Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor - Contacts and Locations

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00021047

Locations


United States, Maryland
	Center for Cancer Research
	Bethesda, Maryland, United States, 20889-5105
	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
	Bethesda, Maryland, United States, 20892-1182

United States, Virginia
	Naval Medical Center, Portsmouth
	Portsmouth, Virginia, United States, 23708-2197

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators


Investigator:	Brian P. Monahan, MD, FACP	National Cancer Institute (NCI)

Study Chair:	Eva Szabo, MD	National Cancer Institute (NCI)